{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T14:22:15Z","timestamp":1789914135339,"version":"4.0.1"},"reference-count":29,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"vor","delay-in-days":22,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J Int AIDS Soc."],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The 13th IAS Conference on HIV Science, held in Kigali, Rwanda (13\u201317 July 2025), highlighted key advances in clinical research. Presentations focused on sustaining HIV treatment and prevention amid financial constraints, innovations in long\u2010acting oral antiretrovirals, and the management of comorbidities and co\u2010infections, particularly tuberculosis (TB) and mpox.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Significant progress was reported on long\u2010acting oral antiretrovirals, including a weekly treatment regimen and a promising monthly option for pre\u2010exposure prophylaxis. These strategies could expand the current antiretroviral therapy (ART) portfolio to better meet individual needs. Additionally, the use of currently available long\u2010acting regimens in non\u2010suppressed individuals warrants further exploration, supported by growing evidence of their potential in this clinical context. Intermittent ART, previously studied as a means to reduce toxicity, is now gaining attention as a potential cost\u2010saving strategy. However, more research is needed to define its role across diverse settings. While data from high\u2010income countries is encouraging, results have been less favourable in resource\u2010limited settings and among key populations such as adolescents. Two\u2010drug and injectable regimens, increasingly used and supported by international guidelines in high\u2010income settings, are now being explored in resource\u2010limited contexts and incorporated into clinical guidelines\u2014narrowing the gap between recommendations for high\u2010 and low\u2010income regions. As the ART portfolio evolves towards regimens without tenofovir, hepatitis B reactivation emerged as a key topic at the conference. Management of TB, a long\u2010standing clinical challenge, was also addressed in Kigali with trial data supporting early empiric TB treatment and the safety of same\u2010day ART initiation in selected clinical scenarios. The UNITY trial on tecovirimat for mpox treatment showed no significant clinical benefit, underscoring the need to revise current management guidelines. Research on comorbidities examined ART\u2010associated weight gain, showing that switching ART once obesity is established has a limited impact on weight outcomes. Studies in paediatric populations highlighted predictors of treatment failure and the benefits of dolutegravir\u2010based regimens.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In the face of growing economic pressures, innovation in HIV treatment and prevention remains essential. The conference emphasized the importance of sustainable public health strategies and individualized care approaches to ensure continued progress in the global HIV response.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/jia2.70088","type":"journal-article","created":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T09:06:52Z","timestamp":1774256812000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Overcoming barriers, driving progress: Clinical science at IAS 2025"],"prefix":"10.1002","volume":"29","author":[{"given":"Ezequiel","family":"Cordova","sequence":"first","affiliation":[{"name":"Infectious Diseases Unit Hospital Cosme Argerich  Buenos Aires Argentina"},{"name":"Clinical Research Unit Fundaci\u00f3n IDEAA  Buenos Aires Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simiso","family":"Sokhela","sequence":"additional","affiliation":[{"name":"Ezintsha University of the Witwatersrand  Johannesburg South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmini","family":"Alagaratnam","sequence":"additional","affiliation":[{"name":"Department of HIV Medicine &amp; Sexual Health Chelsea &amp; Westminster Hospital NHS Foundation Trust  London UK"},{"name":"Section of Virology Department of Infectious Disease Imperial College London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Ambrosioni","sequence":"additional","affiliation":[{"name":"HIV Unit Infectious Disease Service Hospital Clinic\u2010IDIBAPS University of Barcelona  Barcelona Spain"},{"name":"CIBERINFEC ISCIII  Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,3,23]]},"reference":[{"key":"e_1_2_9_2_1","unstructured":"AIDS crisis and the power to transform: UNAIDS Global AIDS Update 2025.Geneva:Joint United Nations Programme on HIV\/AIDS;2025."},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)00771-8"},{"key":"e_1_2_9_4_1","unstructured":"CresswellFV KafeeroP NorcrossC TumusiimeV Achieng OmbajoL GarrettN et\u00a0al.Long\u2010acting cabotegravir and rilpivirine in adults with suboptimal HIV control in sub\u2010Saharan Africa: the IMPALA trial 48\u2010week results.2025:OAS0105LB."},{"key":"e_1_2_9_5_1","unstructured":"HsuR SensionM FuscoJS BrunetL LevisB CochranQ et\u00a0al.Real\u2010world effectiveness of CAB+RPV LA in individuals with HIV viremia at therapy initiation.2025:OAB0104."},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae500"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(24)00289-5"},{"key":"e_1_2_9_8_1","unstructured":"BahemukaU AnkundaV TumusiimeV KafeeroP NorcrossC GarrettN et\u00a0al.Is long\u2010acting injectable antiretroviral therapy safe in countries with high hepatitis B prevalence?: Insights from the IMPALA study.2025:OAB0202."},{"key":"e_1_2_9_9_1","unstructured":"FadigaF GabillardDMR MohR NiangoranS DialloZ PodaA et\u00a0al.First experience of dual antiretroviral maintenance regimen in West and Central Africa compared with continuing 3\u2010drug current antiretroviral regimens (CARs): week 96 results from the MODERATO trial (ANRS \u2010MIE 12372).2025:OAB0103."},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.13542"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.22246"},{"key":"e_1_2_9_12_1","unstructured":"FordN.Recommendations on HIV clinical treatment including long\u2010acting injectables management of advance HIV disease and service delivery and integration. From: What's new in WHO guidelines: advancing prevention testing and treatment for impact and sustainability.2025. Satellite symposium #11 IAS 2025."},{"key":"e_1_2_9_13_1","unstructured":"MolinaJM RamgopalMN KatlamaC CunninghamDL HaginsDP BraunDL et\u00a0al.A double\u2010blind active\u2010controlled phase 2b study to evaluate the efficacy and safety of ulonivirine in combination with islatravir in virologically suppressed adults living with HIV\u20101.2025:OAB0102."},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofae631.015"},{"key":"e_1_2_9_15_1","unstructured":"MayerK KotzeP LombaardJ CaracoY PeerA PoovanN et\u00a0al.Safety and pharmacokinetics of MK\u20108527 oral once\u2010monthly: a phase 2 study in adults at low risk of HIV\u20101 exposure.2025:OAS0106LB."},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103233"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(25)00074-8"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352\u20103018(25)00192\u20104"},{"key":"e_1_2_9_19_1","unstructured":"HillA FairheadC ManaluS VenterF CollinsS LandmanR et\u00a0al.Systematic review and meta\u2010analysis of the efficacy of intermittent antiretroviral therapy dosing: a crisis response to the sudden cuts in USAID and PEPFAR funding.2025:OAB0106LB."},{"key":"e_1_2_9_20_1","unstructured":"KekitiinwaA JenningsA Bwakura DangarembiziM KityoC SiikaA MoherndranA et\u00a0al.Short cycle antiretroviral therapy (ART) with weekends off is inferior to continuous ART in adolescents living with HIV receiving tenofovir disoproxil fumarate\/lamivudine\/dolutegravir (TLD) in sub\u2010Saharan Africa: BREATHER Plus 96\u2010week results.2025:OAS0104LB."},{"key":"e_1_2_9_21_1","unstructured":"GrinsztejnB OlsenI HaviariS CahnP DaabekN CardosoS et\u00a0al.Tecovirimat for mpox\u2014primary clinical outcome results from the randomized part of the Unity trial.2025:OAM01."},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-021-00547-y"},{"key":"e_1_2_9_23_1","unstructured":"HeysellS MpagamaS NullM SaidB NuwagiraE ThomasE et\u00a0al.A two\u2010by\u2010two factorial randomized trial of immediate and\/or sepsis\u2010specific dose anti\u2010tuberculosis therapy to improve mortality for adults with sepsis and HIV in East Africa.2025:OAB0502."},{"key":"e_1_2_9_24_1","doi-asserted-by":"crossref","unstructured":"GerberF SemphereR LukauB MahlatsiP Sanchez\u2010SamaniegoG MolatelleM et\u00a0al.Same\u2010day antiretroviral therapy initiation in people with HIV and presumptive tuberculosis: a randomized non\u2010inferiority trial in Lesotho and Malawi (SaDAPT).2025:OAB0503.","DOI":"10.2139\/ssrn.5233286"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(20)30241-1"},{"key":"e_1_2_9_26_1","unstructured":"ElionR GruberJ RadtchenkoJ DunbarM Prata MenezesN EronJ et\u00a0al.Predictors of weight gain among people with HIV (PWH) over 3\u2010year period.2025:OAB0204."},{"key":"e_1_2_9_27_1","unstructured":"KoetheJ LakeJ KantorA SmeatonL ErlandsonK MoranL et\u00a0al.A5391: a randomized multicenter 3\u2010arm controlled trial for people with obesity on integrase inhibitors and tenofovir alafenamide switching to doravirine with or without tenofovir disoproxil fumarate (The DO\u2010IT Trial).2025:OAB0206LB."},{"key":"e_1_2_9_28_1","unstructured":"WyncollJ ArcharyM KamolrattanaR MujuruHR KekitiinwaAR ViolariA et\u00a0al.Predictors of treatment failure in children living with HIV starting first\u2010line antiretroviral therapy in the ODYSSEY trial.2025:OAB0301."},{"key":"e_1_2_9_29_1","unstructured":"VannappagariV AlbanoJ RagoneL ScheuerleA MofensonL ShortW et\u00a0al.Pregnancy and neonatal outcomes following prenatal exposure to cabotegravir (CAB): data from The Antiretroviral Pregnancy Registry (APR).2025:OAB0402."},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2407001"}],"container-title":["Journal of the International AIDS Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jia2.70088","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jia2.70088","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jia2.70088","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T06:36:02Z","timestamp":1774766162000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jia2.70088"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.1002\/jia2.70088"],"URL":"https:\/\/doi.org\/10.1002\/jia2.70088","archive":["Portico"],"relation":{},"ISSN":["1758-2652","1758-2652"],"issn-type":[{"value":"1758-2652","type":"print"},{"value":"1758-2652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"2025-10-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70088"}}